



Bal Pharma Limited

01.04.2017

To,
The Manager-Listing
National Stock Exchange of India Ltd
Mumbai.

To,
The Manager-Listing
Bombay Stock Exchange Ltd
Mumbai.

Dear Sir,

Sub:- Disclosure under Regulation 30 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

With reference to the above, we submit to the exchange disclosures received from the Promoter and Promoter group of the Company in Compliance with the provisions of Regulation 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for the Financial Year ended 31.03.2017

Please take the same on record.

Thanking You.

For Bal Pharma Limited

Authorized Signatory



CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057/48

Email : info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph: 41570813/19 Fax : 41570820

To,

31.03.2017

The Manager- Listing
NSE
Mumbai

Dear Sir,

Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2017 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,



Shailesh Siroya

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) AND 30(2) OF SEBI (Substantial Acquisition of Shares and Takeovers) REGULATIONS, 2011.

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders :	a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. OR b) Name of the promoter(s), member of promoter group and PAC with him.		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of :			
a) Shares	12,70,759	8.97%	8.97%
b) Voting Rights(otherwise then by shares)			
c) Warrants			
d) Convertible Securities			
e) Any other instrument that would entitle the holder to receive shares in the TC.			
Total	12,70,759	8.97%	8.97%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.

Note :

1.In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place : Bangalore

Date :31.03.2017


Shailesh Siroya

To,

31.03.2017

The Manager- Listing
NSE
Mumbai

Dear Sir,

Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2017 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,



Subbarao Prasanna

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) AND 30(2) OF SEBI (Substantial Acquisition of Shares and Takeovers) REGULATIONS, 2011.

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders : a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. OR b) Name of the promoter(s), member of promoter group and PAC with him.	NA SUBBA RAO PRASANNA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of : a) Shares b) Voting Rights(otherwise then by shares) c) Warrants d) Convertible Securities e) Any other instrument that would entitle the holder to receive shares in the TC.	20,200	0.14%	0.14%
Total	20,200	0.14%	0.14%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.

Note :

1.In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place : Bangalore

Date :31.03.2017



Subbarao Prasanna

To,

31.03.2017

The Manager- Listing
NSE
Mumbai

Dear Sir,


Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2017 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,



Anita Siroya

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) AND 30(2) OF SEBI (Substantial Acquisition of Shares and Takeovers) REGULATIONS, 2011.

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders :	a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. OR b) Name of the promoter(s), member of promoter group and PAC with him. NA ANITA SIROYA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of :			
a) Shares	10,18,540	7.19%	7.19%
b) Voting Rights(otherwise then by shares)			
c) Warrants			
d) Convertible Securities			
e) Any other instrument that would entitle the holder to receive shares in the TC.			
Total	10,18,540	7.19%	7.19%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.

Note :

1.In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place : Bangalore

Date :31.03.2017

Anita Siroya
ANITA SIROYA

To,

31.03.2017

The Manager- Listing
NSE
Mumbai

Dear Sir,

Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2017 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,



ANAND SURANA

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) AND 30(2) OF SEBI (Substantial Acquisition of Shares and Takeovers) REGULATIONS, 2011.

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders :			
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.	NA		
OR			
b) Name of the promoter(s), member of promoter group and PAC with him.	ANAND SURANA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of :			
a) Shares	5,25,686	3.71%	3.71%
b) Voting Rights(otherwise then by shares)			
c) Warrants			
d) Convertible Securities			
e) Any other instrument that would entitle the holder to receive shares in the TC.			
Total	5,25,686	3.71%	3.71%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.

Note :

1.In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place : Bangalore

Date : 31.03.2017


ANAND SURANA

To,

31.03.2017

The Manager- Listing
NSE
Mumbai

Dear Sir,

Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2017 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,

MS

Monica Surana

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) AND 30(2) OF SEBI (Substantial Acquisition of Shares and Takeovers) REGULATIONS, 2011.

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders : a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. OR b) Name of the promoter(s), member of promoter group and PAC with him.	NA MONICA SURANA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of : a) Shares b) Voting Rights(otherwise then by shares) c) Warrants d) Convertible Securities e) Any other instrument that would entitle the holder to receive shares in the TC.	1,79,909	1.27%	1.27%
Total	1,79,909	1.27%	1.27%


(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.

Note :

1.In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place : Bangalore

Date :31.03.2017

Ms 
Monica Surana

To,

31.03.2017

The Manager- Listing
NSE
Mumbai

Dear Sir,

Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2017 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,


Dilip Surana

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) AND 30(2) OF SEBI (Substantial Acquisition of Shares and Takeovers) REGULATIONS, 2011.

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders :			
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.	NA		
OR			
b) Name of the promoter(s), member of promoter group and PAC with him.	DILIP SURANA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of :			
a) Shares	4,74,994	3.35%	3.35%
b) Voting Rights(otherwise then by shares)			
c) Warrants			
d) Convertible Securities			
e) Any other instrument that would entitle the holder to receive shares in the TC.			
Total	4,74,994	3.35%	3.35%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.

Note :

1.In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place : Bangalore

Date :31.03.2017

DS 
Dilip Surana

To,

31.03.2017

The Manager- Listing
NSE
Mumbai

Dear Sir,

Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2017 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,



Dilip Surana(HUF)

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) AND 30(2) OF SEBI (Substantial Acquisition of Shares and Takeovers) REGULATIONS, 2011.

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders :			
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.	NA		
OR			
b) Name of the promoter(s), member of promoter group and PAC with him.	DILIP SURANA(HUF)		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of :			
a) Shares	1,69,995	1.20%	1.20%
b) Voting Rights(otherwise then by shares)			
c) Warrants			
d) Convertible Securities			
e) Any other instrument that would entitle the holder to receive shares in the TC.			
Total	1,69,995	1.20%	1.20%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.

Note :

1. In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place : Bangalore

Date : 31.03.2017

DS 
Dilip Surana(HUF)

To,

31.03.2017

The Manager- Listing
NSE
Mumbai

Dear Sir,

Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2017 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,

For MICRO LABS LIMITED


Authorized Signatory

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) AND 30(2) OF SEBI (Substantial Acquisition of Shares and Takeovers) REGULATIONS, 2011.

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders : a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. OR b) Name of the promoter(s), member of promoter group and PAC with him.	NA MICRO LABS LIMITED		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of : a) Shares b) Voting Rights(otherwise then by shares) c) Warrants d) Convertible Securities e) Any other instrument that would entitle the holder to receive shares in the TC.	13,10,836	9.25%	9.25%
Total	13,10,836	9.25%	9.25%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.


Note :

1.In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place : Bangalore

Date :31.03.2017

For MICRO LABS LIMITED


Authorized Signatory

To,

31.03.2017

The Manager- Listing
NSE
Mumbai

Dear Sir,

Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2017 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,

AS 

Archana Surana

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) AND 30(2) OF SEBI (Substantial Acquisition of Shares and Takeovers) REGULATIONS, 2011.

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders : a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. OR b) Name of the promoter(s), member of promoter group and PAC with him.	NA ARCHANA SURANA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of : a) Shares b) Voting Rights(otherwise then by shares) c) Warrants d) Convertible Securities e) Any other instrument that would entitle the holder to receive shares in the TC.	2,84,996	2.01%	2.01%
Total	2,84,996	2.01%	2.01%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.

Note :

1.In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place : Bangalore

Date :31.03.2017

AS 
Archana Surana

To,

31.03.2017

The Manager- Listing
NSE
Mumbai

Dear Sir,

Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2017 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,

Jivi D. Siroya
Jivi Dheerajmal Siroya

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) AND 30(2) OF SEBI (Substantial Acquisition of Shares and Takeovers) REGULATIONS, 2011.

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders :			
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.	NA		
OR			
b) Name of the promoter(s), member of promoter group and PAC with him.	JIVI DHEERAJMAL SIROYA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of :			
a) Shares	46,080	0.33%	0.33%
b) Voting Rights(otherwise then by shares)			
c) Warrants			
d) Convertible Securities			
e) Any other instrument that would entitle the holder to receive shares in the TC.			
Total	46,080	0.33%	0.33%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.

Note :

1. In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place : Bangalore

Date : 31.03.2017

Jivi D. Siroya
Jivi Dheerajmal Siroya

To,

31.03.2017

The Manager- Listing
NSE
Mumbai

Dear Sir,


Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2017 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,



Anita Chandraprakash Siroya

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) AND 30(2) OF SEBI (Substantial Acquisition of Shares and Takeovers) REGULATIONS, 2011.

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders :			
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.	NA		
OR b) Name of the promoter(s), member of promoter group and PAC with him.	ANITA CHANDRAPRAKASH SIROYA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of :			
a) Shares	1,22,687	0.87%	0.87%
b) Voting Rights(otherwise then by shares)			
c) Warrants			
d) Convertible Securities			
e) Any other instrument that would entitle the holder to receive shares in the TC.			
Total	1,22,687	0.87%	0.87%


(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.

Note :

1.In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place:Bangalore

Date :31.03.2017



Anita Chandraprakash Siroya

To,

31.03.2017

The Manager- Listing
NSE
Mumbai

Dear Sir,

Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2017 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,



Chandraprakash Dheerajmal Siroya

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) AND 30(2) OF SEBI (Substantial Acquisition of Shares and Takeovers) REGULATIONS, 2011.

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders :	a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. OR a) Name of the promoter(s), member of promoter group and PAC with him.		
	NA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of :			
a) Shares	4,86,420	3.43%	3.43%
b) Voting Rights(otherwise then by shares)			
c) Warrants			
d) Convertible Securities			
e) Any other instrument that would entitle the holder to receive shares in the TC.			
Total	4,86,420	3.43%	3.43%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.

Note :

1. In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place : Bangalore

Date : 31.03.2017



Chandraprakash Dheerajmal Siroya

To,

31.03.2017

The Manager- Listing
NSE
Mumbai

Dear Sir,


Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2017 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,



Shrenik D Siroya

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) AND 30(2) OF SEBI (Substantial Acquisition of Shares and Takeovers) REGULATIONS, 2011.

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders :			
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.	NA		
OR b) Name of the promoter(s), member of promoter group and PAC with him.	SHRENIK D SIROYA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of :			
a) Shares	3,74,700	2.64%	2.64%
b) Voting Rights(otherwise then by shares)			
c) Warrants			
d) Convertible Securities			
e) Any other instrument that would entitle the holder to receive shares in the TC.			
Total	3,74,700	2.64%	2.64%


(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.

Note :

1.In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place:Bangalore

Date :31.03.2017



Shrenik D Siroya